{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T03:35:30Z","timestamp":1777952130436,"version":"3.51.4"},"reference-count":53,"publisher":"Informa UK Limited","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"BridgeBio Pharma, Inc. San Francisco, CA"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Cardiology"],"published-print":{"date-parts":[[2026,2,1]]},"DOI":"10.1080\/14796678.2025.2610641","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T05:32:27Z","timestamp":1770615147000},"page":"119-133","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Acoramidis in transthyretin amyloid cardiomyopathy: expanding evidence from ATTRibute-CM"],"prefix":"10.1080","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0233-7881","authenticated-orcid":false,"given":"Nitasha","family":"Sarswat","sequence":"first","affiliation":[{"name":"University of Chicago","place":["Chicago, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3503-4203","authenticated-orcid":false,"given":"Amrut V","family":"Ambardekar","sequence":"additional","affiliation":[{"name":"University of Colorado Anschutz Medical Campus","place":["Aurora, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4024-3691","authenticated-orcid":false,"given":"Kevin M","family":"Alexander","sequence":"additional","affiliation":[{"name":"Stanford University School of Medicine","place":["Palo Alto, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2124-2151","authenticated-orcid":false,"given":"Sarah AM","family":"Cuddy","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital","place":["Boston, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3024-9563","authenticated-orcid":false,"given":"Lily","family":"Stern","sequence":"additional","affiliation":[{"name":"Smidt Heart Institute","place":["Los Angeles, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9586-835X","authenticated-orcid":false,"given":"Steen Hvitfeldt","family":"Poulsen","sequence":"additional","affiliation":[{"name":"Aarhus University","place":["Aarhus, Denmark"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5243-8985","authenticated-orcid":false,"given":"Carsten","family":"Tsch\u00f6pe","sequence":"additional","affiliation":[{"name":"Clinic for Cardiology, Angiology and Intensive Care Medicine","place":["Berlin, Germany"]},{"name":"Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin","place":["Berlin, Germany"]},{"name":"Humboldt-Universit\u00e4t zu Berlin","place":["Berlin, Germany"]},{"name":"DZHK (German Centre for Cardiovascular Research), Partner Site Berlin","place":["Berlin, Germany"]},{"name":"Berlin Institute of Health (BIH) at Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Center for Regenerative Therapies (BCRT)","place":["Berlin, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8132-2743","authenticated-orcid":false,"given":"Yoshiki","family":"Sekijima","sequence":"additional","affiliation":[{"name":"Shinshu University School of Medicine","place":["Nagano, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9687-9475","authenticated-orcid":false,"given":"Farooq H","family":"Sheikh","sequence":"additional","affiliation":[{"name":"Medstar Health\/Georgetown University School of Medicine","place":["Washington, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1729-7464","authenticated-orcid":false,"given":"Jan M","family":"Griffin","sequence":"additional","affiliation":[{"name":"Medical University of South Carolina","place":["Charleston, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3407-0248","authenticated-orcid":false,"given":"Daniel P","family":"Judge","sequence":"additional","affiliation":[{"name":"Medical University of South Carolina","place":["Charleston, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6174-9232","authenticated-orcid":false,"given":"Julian","family":"Gillmore","sequence":"additional","affiliation":[{"name":"University College London","place":["London, UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6390-6526","authenticated-orcid":false,"given":"Ahmad","family":"Masri","sequence":"additional","affiliation":[{"name":"Oregon Health and Science University","place":["Portland, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2026,2,8]]},"reference":[{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.04.003"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.0442"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716793"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12509-8"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2010.67"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2022.11.022"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3002473"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2011.12.060"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.202495199"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.113.301273"},{"key":"e_1_3_6_13_1","unstructured":"ATTRUBY\u2122 (acoramidis). US prescribing information. Palo Alto (CA): BridgeBio Pharma Inc.; [updated 2024 Nov; cited 2025 Sep 5]. Available from: https:\/\/attruby.com\/attruby-prescribing-information.pdf"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b00817"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.700"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.03.012"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2305434"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad655.989"},{"key":"e_1_3_6_19_1","unstructured":"VYNDAQEL\u00ae (tafamidis meglumine) and VYNDAMAX\u2122 (tafamidis). US prescribing information. New York (NY): Pfizer Labs Division of Pfizer Inc; [updated 2023 October; cited 2025 Sep 5]. Available from: http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=11685"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805689"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19990615)18:11<1341::AID-SIM129>3.0.CO;2-7"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.11.042"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2025.09.013"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2025.03.542"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2021-319063"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(25)02073-X"},{"key":"e_1_3_6_27_1","volume-title":"Poster presented at: The European Society of Cardiology (ESC) Congress","author":"Sarswat N","year":"2025","unstructured":"Sarswat N, Masri A, Bhatt K, et al. Acoramidis-mediated improvement in NT-proBNP at month 30 compared with placebo in patients with ATTR-CM: results from the ATTRibute-CM study. Poster presented at: The European Society of Cardiology (ESC) Congress; Madrid, Spain; 2025 Aug 29\u2013Sep 1."},{"key":"e_1_3_6_28_1","unstructured":"U.S. FDA approves VYNDAQEL\u00ae and VYNDAMAX\u2122 for use in patients with transthyretin amyloid cardiomyopathy a rare and fatal disease [Internet]. Pfizer Inc.; 2025 [updated 2019 May 6; cited 2025 Jul 30]. Available from: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/u_s_fda_approves_vyndaqel_and_vyndamax_for_use_in_patients_with_transthyretin_amyloid_cardiomyopathy_a_rare_and_fatal_disease"},{"key":"e_1_3_6_29_1","unstructured":"A phase 3 randomized double-blind placebo-controlled study of the efficacy and safety of AG10 in subjects with symptomatic transthyretin amyloid cardiomyopathy (ATTRibute-CM trial) [Internet]. ClinicalTrials.gov; 2024 [updated 2024 Jun 27; cited 2025 Jul 30]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03860935"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(25)01661-4"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx589"},{"key":"e_1_3_6_32_1","volume-title":"Oral presentation presented at: The European Society of Cardiology Heart Failure Congress","author":"Poulsen S","year":"2024","unstructured":"Poulsen S, Gillmore JD, Alexander KM, et al. ATTRibute-CM: ITT sensitivity analysis and sub-analysis comparing acoramidis and placebo in stage 4 CKD. Oral presentation presented at: The European Society of Cardiology Heart Failure Congress; London UK; 2024 Aug 30\u2013Sep 2."},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.26226\/m.65f9bf8ae6f73964e1d4f0f8"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.26226\/m.65f9bf8be6f73964e1d4f437"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.124.072771"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2025.03.017"},{"key":"e_1_3_6_37_1","unstructured":"BEYONTTRA [Summary of product characteristics]. Ennigerloh Germany: Rottendorf Pharma GmbH; [updated 2025 Jun 24; cited 2025 Aug 26]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/beyonttra-epar-product-information_en.pdf"},{"key":"#cr-split#-e_1_3_6_38_1.1","unstructured":"Attruby\u2122 (acoramidis) a near complete TTR stabilizer (\u226590%) approved by FDA to reduce cardiovascular death and cardiovascular-related hospitalization in ATTR-CM patients [Internet]. BridgeBio Pharma Inc. 2025 [updated 2024 Nov 22"},{"key":"#cr-split#-e_1_3_6_38_1.2","unstructured":"cited 2025 Jul 30]. Available from: https:\/\/bridgebio.com\/news\/attruby-acoramidis-a-near-complete-ttr-stabilizer-%E2%89%A590-approved-by-fda-to-reduce-cardiovascular-death-and-cardiovascular-related-hospitalization-in-attr-cm-patients\/"},{"key":"#cr-split#-e_1_3_6_39_1.1","unstructured":"Beyonttra\u00ae (acoramidis) the first near-complete TTR stabilizer (\u226590%) approved by the UK Medicines and Healthcare Products Regulatory Agency to treat ATTR-CM [Internet]. BridgeBio Pharma Inc. 2025 [updated 2025 Apr 28"},{"key":"#cr-split#-e_1_3_6_39_1.2","unstructured":"cited 2025 Jul 30]. Available from: https:\/\/investor.bridgebio.com\/news\/news-details\/2025\/BEYONTTRA-acoramidis-the-First-Near-complete-TTR-Stabilizer-90-Approved-by-the-UK-Medicines-and-Healthcare-Products-Regulatory-Agency-to-Treat-ATTR-CM\/"},{"key":"#cr-split#-e_1_3_6_40_1.1","unstructured":"Beyonttra\u2122 (acoramidis) the first near-complete TTR stabilizer (\u226590%) approved in Japan to treat ATTR-CM [Internet]. BridgeBio Pharma Inc. 2025 [updated 2025 Mar 27"},{"key":"#cr-split#-e_1_3_6_40_1.2","unstructured":"cited 2025 Jul 30]. Available from: https:\/\/investor.bridgebio.com\/news\/news-details\/2025\/beyonttra-acoramidis-the-first-near-complete-ttr-stabilizer-90-approved-in-japan-to-treat-attr-cm-03-27-2025\/default.aspx"},{"key":"#cr-split#-e_1_3_6_41_1.1","unstructured":"Beyonttra\u2122 (acoramidis) the first near complete TTR stabilizer (\u226590%) approved by the European Commission to treat ATTR-CM [Internet]. BridgeBio Pharma Inc. 2025 [updated 2025 Feb 11"},{"key":"#cr-split#-e_1_3_6_41_1.2","unstructured":"cited 2025 Jul 30]. Available from: https:\/\/investor.bridgebio.com\/news\/news-details\/2025\/beyonttra-acoramidis-the-first-near-complete-ttr-stabilizer-90-approved-by-the-european-commission-to-treat-attr-cm-02-11-2025\/default.aspx"},{"key":"e_1_3_6_42_1","unstructured":"BEYONTTRA (acoramidis). Japanese prescribing information. [updated 2025; cited 2025 Dec 4]. Available from: https:\/\/www.pmda.go.jp\/english\/review-services\/reviews\/approved-information\/drugs\/0001.html"},{"key":"e_1_3_6_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.06.033"},{"key":"e_1_3_6_44_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14134785"},{"key":"e_1_3_6_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2023.12.036"},{"key":"e_1_3_6_46_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2409134"},{"key":"e_1_3_6_47_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2300757"},{"key":"e_1_3_6_48_1","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2018.1556156"},{"key":"e_1_3_6_49_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716153"},{"key":"e_1_3_6_50_1","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2022.2091985"},{"key":"e_1_3_6_51_1","unstructured":"A phase 3 randomized multicenter double-blind placebo-controlled study of acoramidis for transthyretin amyloidosis prevention in the young (ACT-EARLY trial) [Internet]. ClinicalTrials.gov; 2025 [updated 2025 Jun 5; cited 2025 Jul 30]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06563895"}],"container-title":["Future Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14796678.2025.2610641","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T11:41:50Z","timestamp":1777894910000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14796678.2025.2610641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,1]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,1]]}},"alternative-id":["10.1080\/14796678.2025.2610641"],"URL":"https:\/\/doi.org\/10.1080\/14796678.2025.2610641","relation":{},"ISSN":["1479-6678","1744-8298"],"issn-type":[{"value":"1479-6678","type":"print"},{"value":"1744-8298","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,1]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifca20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifca20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-10-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}